MX2021001064A - Anticuerpos procoagulantes mejorados. - Google Patents

Anticuerpos procoagulantes mejorados.

Info

Publication number
MX2021001064A
MX2021001064A MX2021001064A MX2021001064A MX2021001064A MX 2021001064 A MX2021001064 A MX 2021001064A MX 2021001064 A MX2021001064 A MX 2021001064A MX 2021001064 A MX2021001064 A MX 2021001064A MX 2021001064 A MX2021001064 A MX 2021001064A
Authority
MX
Mexico
Prior art keywords
factor
methods
antibodies
fixa
activated form
Prior art date
Application number
MX2021001064A
Other languages
English (en)
Inventor
Østergaard Henrik
Jianhe Chen
Karina Thorn
Bjarne Gram Hansen
Mikkel Nors Harndahl
Zhiru Yang
Per J Greisen
Eva Johansson
Anders Svensson
Haisun Zhu
Rong Zhou
Laust Bruun Johnsen
Morten Grønbech Rasch
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2021001064A publication Critical patent/MX2021001064A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos procoagulantes multiespecíficos capaces de unirse al Factor IX (FIX) de coagulación y/o la forma activada de este Factor Ixa (FIXa), y Factor X (FX) y/o la forma activada de este Factor Xa (FXa) y que promueven la activación del FX por parte del FIXa, anticuerpos que se unen a sus epítopos o partes de estos y métodos y composición para tratar sujetos que padecen una coagulopatía tal como hemofilia A, así como también kits, métodos de fabricación y métodos de uso.
MX2021001064A 2018-08-01 2019-07-31 Anticuerpos procoagulantes mejorados. MX2021001064A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2018097834 2018-08-01
CN2018099339 2018-08-08
EP18193191 2018-09-07
PCT/EP2019/070628 WO2020025672A1 (en) 2018-08-01 2019-07-31 Improved procoagulant antibodies

Publications (1)

Publication Number Publication Date
MX2021001064A true MX2021001064A (es) 2021-04-12

Family

ID=67480228

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001064A MX2021001064A (es) 2018-08-01 2019-07-31 Anticuerpos procoagulantes mejorados.

Country Status (18)

Country Link
US (1) US20230058721A1 (es)
EP (1) EP3830135A1 (es)
JP (3) JP6761142B1 (es)
KR (2) KR20210091839A (es)
CN (3) CN117384296A (es)
AU (1) AU2019313550B2 (es)
BR (1) BR112021000823A2 (es)
CA (1) CA3113797A1 (es)
CL (1) CL2021000186A1 (es)
CO (1) CO2021001046A2 (es)
IL (1) IL280239A (es)
MA (1) MA53322A (es)
MX (1) MX2021001064A (es)
PE (1) PE20211399A1 (es)
PH (1) PH12021550117A1 (es)
SG (1) SG11202100418PA (es)
TW (1) TWI716059B (es)
WO (1) WO2020025672A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115052898A (zh) * 2020-01-30 2022-09-13 诺和诺德股份有限公司 双特异性因子viii模拟抗体
KR20230130558A (ko) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체의 월 1회 투여 방법
KR20230130561A (ko) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법
KR20230130560A (ko) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체의 주 1회 투여 방법
WO2024008904A2 (en) 2022-07-08 2024-01-11 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2288600C (en) * 1997-05-02 2010-06-01 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271186A1 (en) * 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US20100003254A1 (en) * 2005-04-08 2010-01-07 Chugai Seiyaku Kabushiki Kaisha Antibody Substituting for Function of Blood Coagulation Factor VIII
PT2644698T (pt) 2010-11-17 2018-01-31 Chugai Pharmaceutical Co Ltd Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
JP6348900B2 (ja) * 2012-05-10 2018-06-27 バイエル ファーマ アクチエンゲゼルシャフト 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途
EP3066132A2 (en) * 2013-11-07 2016-09-14 Novo Nordisk A/S Novel methods and antibodies for treating coagulapathy
TWI700300B (zh) * 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
KR102057767B1 (ko) * 2015-04-17 2019-12-19 에프. 호프만-라 로슈 아게 응고 인자 및 다중특이적 항체의 조합 요법
WO2018098363A2 (en) * 2016-11-23 2018-05-31 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
EP3848396A1 (en) 2017-02-01 2021-07-14 Novo Nordisk A/S Antibodies recognising factor ix and x for use in promoting coagulation
US11220554B2 (en) * 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies

Also Published As

Publication number Publication date
JP2022084858A (ja) 2022-06-07
CN112513096B (zh) 2023-08-25
WO2020025672A9 (en) 2020-04-23
AU2019313550B2 (en) 2024-02-08
SG11202100418PA (en) 2021-02-25
JP7355874B2 (ja) 2023-10-03
CN117384296A (zh) 2024-01-12
CN112513096A (zh) 2021-03-16
PE20211399A1 (es) 2021-07-27
JP7094314B2 (ja) 2022-07-01
JP6761142B1 (ja) 2020-09-23
US20230058721A1 (en) 2023-02-23
TW202007696A (zh) 2020-02-16
CL2021000186A1 (es) 2021-07-02
MA53322A (fr) 2021-11-10
CN117343188A (zh) 2024-01-05
KR20210091839A (ko) 2021-07-22
AU2019313550A1 (en) 2021-02-04
CO2021001046A2 (es) 2021-04-30
WO2020025672A1 (en) 2020-02-06
CA3113797A1 (en) 2020-02-06
PH12021550117A1 (en) 2021-10-04
BR112021000823A2 (pt) 2021-04-13
KR20210040389A (ko) 2021-04-13
TWI716059B (zh) 2021-01-11
EP3830135A1 (en) 2021-06-09
IL280239A (en) 2021-03-25
KR102382743B1 (ko) 2022-04-12
JP2020115863A (ja) 2020-08-06
JP2020530449A (ja) 2020-10-22

Similar Documents

Publication Publication Date Title
PH12019501708A1 (en) Procoagulant antibodies
PH12021550117A1 (en) Improved procoagulant antibodies
PH12019501126A1 (en) Bispecific antibodies binding to coagulation factor ix and ciagulation factor x
CY1124118T1 (el) Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
MX2018013038A (es) Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
DK1951759T3 (da) Anti-EGFR-antistoffer
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
EA202092187A1 (ru) Способы лечения эпителиоидно-клеточных опухолей
MX2014015830A (es) Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
MX2012007153A (es) Nuevos anticuerpos antagonistas y sus fragmentos fab contra gpvi y sus usos.
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
TR201819781T4 (tr) Kanama Bozukluklarının Tedavisi İçin Modifiye Serpinler
EA201590918A1 (ru) Антитела к bmp-6
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2022000203A (es) Composiciones de liberacion sostenida de endoxifeno.
MX2019013700A (es) Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand.
AR114539A1 (es) Anticuerpos procoagulantes mejorados
EA202092640A1 (ru) Способы и композиции для лечения хронической крапивницы
EA201991246A1 (ru) Моно- и биспецифические антитела, связывающиеся с фактором коагуляции ix и фактором коагуляции x